Shore Capital Reaffirms “Buy” Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “buy” rating restated by investment analysts at Shore Capital in a report issued on Thursday, Marketbeat reports.

hVIVO Trading Up 5.4 %

LON:HVO opened at GBX 15.81 ($0.21) on Thursday. The company has a market cap of £111.87 million, a PE ratio of 6.52 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The company has a 50 day simple moving average of GBX 16.07 and a two-hundred day simple moving average of GBX 20.79. hVIVO has a 12 month low of GBX 12.60 ($0.16) and a 12 month high of GBX 31 ($0.41).

hVIVO (LON:HVO) last issued its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Research analysts forecast that hVIVO will post 1.5492958 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Yamin Mo’ Khan sold 3,062,246 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($681,389.82). 14.03% of the stock is currently owned by insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.